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Background
With potentially life-long treatment of patients with HIV
it is crucial to ensure antiretroviral treatment is used in
such a way that adverse effects are reduced as much as pos-
sible.
Methods
We illustrate methodology of the number needed to treat
to harm (NNTH) using the recent findings from the D:A:D
study (90% increased relative risk, RR = 1.90, of myocar-
dial infarction [MI] in patients on abacavir compared with
patients not receiving abacavir) [1]. We assume this RR
remains constant across the range of underlying risk of
MI. NNTH was calculated as 1/[(underlying risk of MI ×
1.90) – underlying risk of MI], where the underlying risk
of MI is calculated for the next 5 years using a parametric
statistical model based on the Framingham score [2]http:/
/www.cphiv.dk/TOOLS/tabid/282/Default.aspx.
Summary of results
The relationship between NNTH and underlying risk of
MI is exponential whereas the relationship between abso-
lute risk increase and underlying risk of MI is linear (Fig-
ure 1). The NNTH shows a steep decrease from 185 to 5
when the underlying risk of MI increases from 0.6% to
20%. The lowest NNTH values are observed in the high
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The relation between number needed to treat to harm (NNTH), absolute risk increase (ARI) and the underlying risk of MIFigu e 1
The relation between number needed to treat to harm 
(NNTH), absolute risk increase (ARI) and the underlying risk 
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risk group, while the most dynamic changes in NNTH is
in the low risk group.
A low risk profile was used to illustrate the relationship
between NNTH and underlying risk of MI in clinical
terms; a male, aged 40, non-smoker with no diabetes, no
ECG-left ventricle hypertrophy (ECG-LVH), systolic blood
pressure (sBP) of 120 mmHg, total cholesterol (TC) of
170 mg/dL (4.4 mmol/L) and HDL of 60 mg/dL (1.5
mmol/L). For this profile, underlying risk of MI is 0.1%
and NNTH = 1,111. The NNTH drops from 1,111 to 555
if diabetes, ECG-LVH or TC = 240 mg/dl (6.2 mmol/L) is
diagnosed (Table 1). The NNTH drops further to 370 for
sBP = 160 mmHg or HDL = 35 mg/dl (0.9 mmol/L) and
to 277 for smoking. When two risk components are unfa-
vourable at the same time the NNTH drops from 1,111 to
around 100 for most pairs, except smoking and unfavour-
able HDL, for which NNTH = 69. The NNTH becomes 7
and the underlying risk of MI 15% when all risk factors are
unfavourable. Practical tools (including 3D graphs) to
explore these relations and guide interventions for indi-
vidual patients have been developed.
Conclusion
It is possible to increase NNTH values for any group of
patients on abacavir by decreasing the underlying risk of
MI. Therefore, if underlying risk of MI can be reduced, the
NNTH for a given therapy will increase, meaning that the
therapy can be administered to more people without caus-
ing additional harm.
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Table 1: 
Change in factors contributing to underlying risk Underlying risk of MI in 5 years (%) NNTH
Example low risk profile (described in text) 0.1 1111
If total cholesterol 240 mg/dL (6.2 mmol/L) 0.2 555
If diabetes 0.2 555
If ECG-LVH 0.2 555
If sBP 160 mmHg 0.3 370
If HDL 35 mg/dL (0.9 mmol/L) 0.3 370
If smoking 0.4 277
If HDL and total cholesterol unfavourable 0.8 138
If smoking and diabetes 1.1 101
If smoking and total cholesterol unfavourable 1.0 111
If smoking and sBP 160 mmHg 1.3 85
If smoking and HDL unfavourable 1.6 69
If smoking and lipids unfavourable 3.1 35
If all unfavourable combined (excluding ECG-LVH) 10.1 11
If all unfavourable combined (including ECG-LVH) 15.0 7Page 2 of 2
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